Answers are grounded in this paper and cite their sources.
Background People at high risk of cutaneous melanoma are recommended to undertake regular skin self‐examination (SSE), but the effectiveness of this is uncertain. Objectives To find, assess, and synthesise all randomised controlled trials (RCTs) of interventions to improve SSE in people at high risk of melanoma. Methods We searched Medline, Cochrane Central, and Embase from inception to 21 March 2024, for RCTs in a clinical setting that evaluated interventions to improve SSE practice. Results From 2358 records screened, 13 eligible RCTs were identified (4286 participants) from the United States of America ( n = 8), United Kingdom ( n = 3), France ( n = 1) and Australia ( n = 1). Trial size ranged from 100 to 728 participants at high risk of melanoma; mean [SD] age ranged from 38 [14.5] to 59 [12] years; 47% to 80% were women. There was low‐certainty evidence that interventions improved SSE practice ( n = 13 trials). Interventions included combinations of the following: education by trained practitioners (in‐person, n = 6), educational material (in‐person n = 7, by mail n = 4, by website n = 2), personalised risk assessments ( n = 1), smartphone applications ( n = 2), other digital applications/websites ( n = 2) and reminder systems (by text n = 1, in‐application prompts n = 2). There was low‐certainty evidence that interventions that included skin check partners increased patient detection of melanoma compared to usual care. These interventions included training, SSE workbooks, SSE kit with ruler and lighted magnifying lens ( n = 2), and training in patient‐led surveillance, mobile dermatoscopes and teledermatology ( n = 1). There was no evidence of intervention effects on the subsequent risk of advanced‐stage melanoma or melanoma mortality. Conclusions Interventions combining education, smartphone and other digital applications, and reminders may improve SSE practice, and those also including skin check partners may increase patient detection of melanoma. Limitations: Trials were small and at high risk of bias for SSE outcomes. Limited evidence on melanoma detection and none on advanced melanoma/melanoma mortality. Trial Registration PROSPERO: CRD42023482128.
No takes yet. Share an insight, caveat, or question.
Gooley et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: